Controls serum phosphorus. ANDA 211917, held by Strides Pharma Intl. Sevelamer Carbonate.
As of Nov 16, 2026, ANDA 211917 (Sevelamer Carbonate), held by Strides Pharma Intl, was first approved by FDA on Sep 8, 2023, with 0 approved supplements and 0 published complete response letters.
Sevelamer carbonate for oral suspension is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 8, 2023 | Original application | Approved | None posted |
| Sevelamer Carbonate800MG/PACKET · for suspension;oral | Sevelamer Carbonate | Rx |
| Sevelamer Carbonate2.4GM/PACKET · for suspension;oral | Sevelamer Carbonate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters